Resources Repository
-
ArticlePublication 2016Cost-Effectiveness of Diagnosing HIV Infection During Early Infancy in South Africa
In this study the clinical impact and cost-effectiveness of four different early infant HIV diagnosis …
In this study the clinical impact and cost-effectiveness of four different early infant HIV diagnosis (EID) testing strategies for HIV-exposed infants in South Africa were compared using a microsimulation model. The strategies included (1) no EID (diagnosis only after illness), (2) and (3) testing once (at birth alone or at 6 weeks of age alone), and (4) testing twice (at birth and 6 weeks of age). Findings showed that the testing at birth alone strategy…
Cost-Effectiveness Analysis | Health/Medicine | Sub-Saharan Africa | Microsimulation | Infectious Diseases | Child/Nutrition -
ArticlePublication 2016Prevention and Treatment of Cardiovascular Disease
This article, published in Cost Effectiveness and Resource Allocation, aims to assess the cost-effectiveness of …
This article, published in Cost Effectiveness and Resource Allocation, aims to assess the cost-effectiveness of prevention and treatment of ischemic heart disease (IHD) and stroke in an Ethiopian setting. Fifteen single interventions and sixteen intervention packages are assessed from a healthcare provider perspective. The results indicate that the escalating burden of CVD and its risk factors warrants timely action. Selected CVD intervention packages could be scaled up at a modest budget increase, but the level…
Cost-Effectiveness Analysis | Health/Medicine | Sub-Saharan Africa | Chronic Disease/Risk | Health Systems -
ReviewPublication 2016Dynamic Transmission Economic Evaluation of Infectious Disease in LMIC
Economic evaluation using dynamic transmission models is important for capturing the indirect effects of infectious …
Economic evaluation using dynamic transmission models is important for capturing the indirect effects of infectious disease interventions. The authors examine the use of these methods in low- and middle-income countries, where infectious diseases constitute a major burden. The review is comprised of two parts: (1) a summary of dynamic transmission economic evaluations across all disease areas published between 2011 and mid-2014 and (2) an in-depth review of mosquito-borne disease studies focusing on health economic methods…
Cost-Effectiveness Analysis | Health/Medicine | Sub-Saharan Africa | Dynamic Transmission | Infectious Diseases | Economics/Finance | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ReviewPublication 2015Provider Costs for Cardiovascular Disease in Low-And Middle-Income Countries: A Systematic Review
The burden of cardiovascular disease (CVD) and related conditions is increasing in low- and middle-income countries. Policy …
The burden of cardiovascular disease (CVD) and related conditions is increasing in low- and middle-income countries. Policy makers need an understanding of the magnitude and drivers of the costs of cardiovascular disease related conditions to make decisions on how to allocate limited health resources. This systematic review of the published literature documents provider-incurred costs of treatment for cardiovascular diseases and risk conditions in low- and middle-income countries. Total costs of treatment were inflated to 2012 US dollars for comparability…
Cost-Effectiveness Analysis | Health/Medicine | Sub-Saharan Africa | Costing Methods | Chronic Disease/Risk | Health Systems | Economics/Finance | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2015Cost-Effectiveness of First-Line Antiretroviral Therapy for HIV-Infected African Children Less Than 3 Years of Age
This article compares the cost-effectiveness of different strategies of first-line antiretroviral therapy (no ART, first-line nevirapine …
This article compares the cost-effectiveness of different strategies of first-line antiretroviral therapy (no ART, first-line nevirapine with second-line lopinavir/ritonavir, and first-line lopinavir/ritonavir with second-line nevirapine) for HIV-infected children less than 3 years of age in Africa, using the Cost-Effectiveness of Preventing AIDS Complications- Pediatric model and data obtained from the International Maternal, Pediatric, and Adolescent Clinical Trial P1060 trial. Results demonstrated that both ART regimens were very cost-effective compared to no ART. First-line lopinavir/ritonavir led to longer…
Cost-Effectiveness Analysis | Health/Medicine | Sub-Saharan Africa | Microsimulation | Infectious Diseases | Child/Nutrition -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Cost-Effectiveness Analysis | Health/Medicine | Sub-Saharan Africa | Health Outcomes | Mathematical Models | Calibration/Validation | Infectious Diseases | Chronic Disease/Risk | Health Systems | Global | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2013Estimated Mortality Impact of Vaccinations 2011–2020 in 73 GAVI Alliance Countries
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted …
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted by the GAVI Alliance and the Bill & Melinda Gates Foundation to estimate the impact of vaccination in 73 countries supported by the GAVI Alliance. The number of deaths averted in persons projected to be vaccinated during 2011–2020 was estimated for ten antigens: hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, rotavirus, Neisseria meningitidis serogroup A, Japanese…
State-Transition | Health/Medicine | Sub-Saharan Africa | Health Outcomes | Mathematical Models | Dynamic Transmission | Microsimulation | Infectious Diseases | Global Governance | Economics/Finance | Science/Technology | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Cost-Effectiveness Analysis | Health/Medicine | Sub-Saharan Africa | Costing Methods | Health Outcomes | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Science/Technology | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2011Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe …
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, they assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, they assessed only screening (with HPV DNA testing up to three times per lifetime or VIA…
Cost-Effectiveness Analysis | Health/Medicine | Sub-Saharan Africa | Microsimulation | Calibration/Validation | Infectious Diseases | Chronic Disease/Risk | Clinical Care | Economics/Finance | Science/Technology